INTRODUCTION: DNA METHYLATION AND BLOOD LIPID LEVELS - WHAT DO WE KNOW?
=======================================================================

Abnormalities in the levels of circulating blood lipids, such as triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), contribute to the pathophysiology of common complex diseases, among them diabetes and cardiovascular diseases (CVDs) -- two of the major causes of morbidity and mortality in industrialized countries \[[@R1]--[@R3]\]. Lipid disorders, also known as dyslipidemias, are primarily a result of unhealthy lifestyle choices: poor diet, lack of physical activity, and overweight, among others. Though these environmental factors are key contributors, the clustering of dyslipidemias in families has also been observed \[[@R4]\], which lends evidence for a genetic influence. Genome-wide association studies (GWAS) have identified a total of 157 common genetic loci associated with lipid levels, though combined these explain 12% or less of trait variance \[[@R5]\]. Consequently, evidence for epigenetic mechanisms playing a role in the regulation of lipid levels is being increasingly recognized. Unlike genetic variation, epigenetic modifications, such as DNA methylation, histone modification, and regulation by RNAs, are dynamically remodeled over time and can be affected by environmental changes \[[@R6]\] and vary according to chromosomal location, alleles, type of cell, or phase of development \[[@R7],[@R8]\]. This dynamism includes reversibility, making epigenetic modifications potentially important pathogenic mechanisms in complex metabolic diseases, and conceivably representing therapeutic targets \[[@R9]\].

Recent advances in omics technology allows a hypothesis-free search of epigenetic modifications, and, in particular, DNA methylation. These have helped identify new loci and pathways involved in lipid metabolism. Whereas there are more than five different DNA modifications known, the most widely studied is the transfer of a methyl group to the C5 position of a cytosine to form a 5-methylcytosine. In conjunction with human lipid traits, DNA methylation is by far the most studied epigenetic process \[[@R9],[@R10]\]. Epigenome-wide association studies (EWAS) have become a powerful instrument to investigate differences in DNA methylation at the population level. Regarding lipid levels, EWAS have highlighted several robustly replicated methylation markers such as cg06500161, annotated to the *ABCG1* gene encoding ATP-binding cassette subfamily G member 1 and cg00574958 within *CPT1A* gene encoding carnitine palmitoyltransferase I.

Petersen *et al.*\[[@R11]\] conducted an EWAS of metabolic traits in whole blood and identified associations between multiple lipids (including cholesterol, sphingolipids, and glycerophospholipids) and lipoproteins, and the methylation level of CpG sites in or in close proximity to the genes 24-dehydrocholesterol reductase (*DHCR24*), thioredoxin-interacting protein (*TXNIP*), solute carrier family 22 member 25 (*SLC25A22*)*, CPT1A,* myosin VC (*MYO5C*), and *ABCG1*\[[@R11]\]. Irvin *et al.*\[[@R12]\] reported that four CpG sites in intron 1 of *CPT1A* were strongly associated with very-low to low-density lipoprotein cholesterol (VLDL-C) and triglycerides. They also showed an inverse association between *CPT1A* methylation (cg00574958) and expression of *CPT1A*. A further EWAS -- Frazier-Wood *et al.*\[[@R13]\] -- in CD4+ T cells revealed associations between LDL-C and VLDL-C levels, and methylation of CpG sites in *CPT1A*\[[@R13]\]. The results were later replicated in blood by Gagnon *et al.*\[[@R14]\]. Pfeiffer *et al.*\[[@R15]\] reported associations in whole blood between DNA methylation and triglycerides for CpG sites mapping to the genes *CPT1A, ABCG1, SREBF1* encoding sterol regulatory element-binding transcription factor 1 and the *SCD* gene encoding stearoyl-CoA desaturase, between DNA methylation and HDL-C for a CpG in *ABCG1*, and between DNA methylation and LDL-C for a CpG in *TXNIP1*. Most of the above reported genes have an important function in lipid metabolism, supporting the hypothesis that epigenetic changes play regulatory roles. Furthermore, several EWAS of lipid-related metabolic phenotypes and diseases, for example, those for BMI, waist circumference \[[@R16]--[@R19]\], and type 2 diabetes (T2D) \[[@R20]--[@R22]\], have uncovered associations with many of the same CpG sites. In this review, we will summarize the latest results from January 2016 to September 2017 concerning EWAS of DNA methylation and lipid traits, and also lipid-related disease. 
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NEWLY DISCOVERED CPG SITES AND THEIR LEVEL OF EVIDENCE
======================================================

Recent EWAS and candidate gene studies have been able to confirm the strong associations reported above between various CpG sites and blood lipid levels across different ethnicities (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) \[[@R23]^▪▪^,[@R24],[@R25]--[@R27],[@R28]^▪▪^,[@R29]--[@R31]\]. Furthermore, they have shown that many CpG sites associated with blood lipids are also associated with lipid metabolism-linked phenotypes and diseases (Table [2](#T2){ref-type="table"}). Recently, Hedman *et al.*\[[@R24]\] reported 25 novel CpG sites not previously found to be associated with lipid levels. The annotated genes were enriched in pathways involved in lipid and amino acid metabolism \[[@R24]\]. Methylation levels at *ABCG1* (cg27243685) were additionally reported in relation to occurrence of CVD events \[[@R24]\]. The authors further showed that triglyceride levels were associated with DNA methylation in the serine metabolism gene *PHGDH* encoding D-3-phosphoglycerate dehydrogenase (cg14476101), a result confirmed by Truong *et al.*\[[@R30]\]. Public database findings support a functional role of cg1476101 in *PHGDH* expression \[[@R30]\].

Wahl *et al.*\[[@R28]^▪▪^\] identified methylation loci associated with BMI in genes \[e.g. *CPT1A, DHCR24, SREBF1*, and *SOCS3* (suppressor of cytokine signaling 3)\] that are involved in lipid metabolism \[[@R28]^▪▪^\]. These associations between BMI and lipid-related CpG sites were confirmed by additional studies in Arab and European populations \[[@R32],[@R33]^▪▪^,[@R34]\]. It was additionally uncovered that the SOCS3 methylation locus is associated with multiple metabolic syndrome traits, including central obesity, fat depots, insulin responsiveness, and plasma lipids (HDL-C and triglycerides) \[[@R27],[@R35]\]. Furthermore, *SOCS3* was found to be associated with lipid levels and insulin resistance in human GWAS and candidate gene studies \[[@R36]\]. Recent EWAS, conducted in Indian, Arab, and Caucasian populations, found that *SOCS3* methylation is associated with BMI and T2D, respectively \[[@R20],[@R32],[@R34]\]. Another interesting methylation site *(TXNIP,* cg19693031) associated with T2D in several studies \[[@R20],[@R22],[@R32],[@R37]\] was also reported to be associated with triglyceride and LDL-C levels \[[@R15],[@R24],[@R38]^▪▪^\].

Differential DNA methylation of five CpG sites annotated to *ABCG1, PHOSPHO1* (phosphoethanolamine/phosphocholine phosphatase), *SOCS3*, *SREBF1*, and *TXNIP* from diabetic versus nondiabetic patients were investigated across different tissues from the same individuals \[[@R31]\]. The results suggest that DNA methylation biomarkers in blood might partly be used as surrogate markers for DNA methylation in inaccessible target tissues, and, importantly, the occurrence of altered DNA methylation in more than one human tissue at the same locus could be mediated by so-called 'metastable epialleles' \[[@R31]\]. Metastable epialleles are alleles that are variably expressed in genetically identical individuals due to epigenetic modifications that were established during early development \[[@R39]\]. BMI-related methylation markers identified by Wahl *et al.*\[[@R28]^▪▪^\] were strongly enriched for CpG sites with intermediate levels of methylation, consistent with the presence of mosaicism, that is, epigenetic heterogeneity, at these loci. The authors performed replication testing in isolated white cell subsets (monocytes, neutrophils, CD4+ T cells, and CD8+ T cells), showing that epigenetic heterogeneity was present at the majority of loci, in each of the cell subsets studied \[[@R28]^▪▪^\]. Wahl *et al.*\[[@R28]^▪▪^\] compared methylation levels between blood, subcutaneous and omental fat, liver, muscle, spleen, and pancreas. Mean methylation levels at the 187 loci correlated moderately to strongly between the tissues, supporting the view that methylation levels in blood are related to methylation patterns in other tissues at the CpG sites examined.

Lai *et al.*\[[@R40]\] showed that eight methylation sites encompassing different genes *LPP* encoding lipoma-preferred partner, *APOA5* encoding apolipoprotein A-V, *SREBF1*, *ABCG1*, and *CPT1A* were associated with triglyceride postprandial responses (TG-PPL), an independent CVD risk factor, after consuming a high-fat meal \[[@R40]\]. These genes had been previously found to be associated with triglyceride and/or HDL-C levels \[[@R15],[@R23]^▪▪^,[@R24],[@R25],[@R38]^▪▪^\]. Data from a Mexican-American study showed cg00574958 and cg17058475 (*CPT1A)* and cg06500161 (*ABCG1*) to be associated with hypertriglyceridemic waist (HTGW), which is defined as large waist circumference combined with high serum triglyceride concentration \[[@R41]\]. Both CpG sites in *CPT1A* were additionally associated with the metabolic syndrome in CD4+ T cells \[[@R42]\]. Recently, *CPT1A* methylation status was also found to be significantly associated with plasma adiponectin, a widely used biomarker for cardiovascular and metabolic risk \[[@R43]\].

So far, EWAS on disorders of lipid metabolism are sparse \[[@R44],[@R45]\]. Sitosterolemia is a rare autosomal recessive sterol storage disease caused by mutations in either of the adenosine triphosphate binding cassette transporter genes *ABCG5* or *ABCG8* encoding ATP-binding cassette subfamily G member 5 or 8, leading to substantially elevated serum plant sterols with moderate to high total cholesterol and LDL-C levels and increased risk of premature atherosclerosis \[[@R46]\]. Interestingly, *ABCG5* methylation was associated with lower LDL-C and reduced risk for coronary artery disease (CAD) \[[@R47],[@R48]\]. In the study by Rask-Andersen *et al.*\[[@R47]\], a total of 6 out of 211 myocardial infarction-associated CpG sites overlapped with previously identified CVD GWAS loci, among them the *ABCG5-ABCG8* locus \[[@R47]\]. The investigation into further lipid classes and studies on disorders of lipid metabolism will provide new and important insights.

CROSS-OMICS: EVIDENCE FROM ADDITIONAL MOLECULAR LAYERS
======================================================

Different molecular layers often have complementary roles to jointly perform a certain biological function \[[@R49]\]. Population-based studies adopted the multiomics approach by integrating these molecular layers into their studies. Whereas this approach has been successfully used for available transcriptome, metabolome, or genetic data, studies are sparse that systematically investigate the interaction of epigenetic mechanisms such as regulatory RNAs or histone modifications \[[@R50]\].

LIPID-ASSOCIATED METHYLATION QUANTITATIVE TRAIT LOCI AND REGULATION OF GENE EXPRESSION
======================================================================================

The variance of lipid levels explained by the currently known genetic variants is modest. All lipid-associated single-nucleotide polymorphisms (SNPs) together explain 12% or less of the variation in plasma lipid traits \[[@R5]\], although the estimated heritable variance of lipids is reported to be at least 50% \[[@R51]\]. This missing heritability may be partly explained by epigenetic processes such as DNA methylation \[[@R52]\]. SNP allele frequencies are known to differ among populations with varying geographic ancestries, suggesting that ethnic differences in DNA methylation could be due to differences in population-specific alleles that shape CpG and global methylation levels. Regulation of gene expression via DNA methylation may explain an additional component of interindividual variation in lipid levels beyond genetic sequence variants. Linking DNA methylation data with gene expression is a promising avenue to see potential downstream effects in lipid metabolism.

Hedman *et al.*\[[@R24]\] found methylation levels of lipid-related CpG sites associated with mRNA expression levels of nearby genes, including cg17901584 (*DHCR24*), cg14476101, cg16246545 (both *PHGDH*), and cg08129017 (*SREBF1*). For the majority (86%) of these associations, levels of methylation and expression were inversely correlated \[[@R24]\]. In agreement with previous studies, they found a large proportion of lipid-related CpG sites to associate with common SNPs in cis. For 12 CpG-transcript pairs, a cis-meQTL was identified and the lead meQTL SNP was significantly associated with both methylation and expression \[[@R24]\].

Volkov *et al.*\[[@R35]\] described methylation quantitative trait loci (meQTLs) in adipose tissue. These meQTLs include reported obesity, lipid, and T2D loci, for example, APOA5, cholesteryl ester transfer protein (CETP), and fatty acid desaturase 2 (FADS2). SNPs in significant meQTLs were also associated with BMI, lipid traits, and glucose and insulin levels \[[@R35]\]. The meQTL at the *APOA5* loci was confirmed by Oliva *et al.*\[[@R53]\] using a candidate gene approach.

Ali *et al.*\[[@R27]\] assessed the relationship between DNA methylation, obesity, and obesity-related phenotypes in peripheral blood mononuclear cells. They found that the methylation status of cg18181703 (*SOCS3*) significantly alters *SOCS3* gene expression \[[@R27],[@R35]\]. Using RNA-seq data, DNA methylation of six CpG sites was associated with the expression of *CPT1A* and *SREBF1* (for triglycerides), *DHCR24* (for LDL-C), and *ABCG1* (for HDL-C) \[[@R23]^▪▪^\]. The results could be confirmed by Braun *et al.*\[[@R25]\]. For *CPT1A*, expression was negatively associated with the methylation of *CPT1A* at both identified CpG sites (cg00574958 and cg17058475). A study by Bekkering *et al.*\[[@R54]\] showed that the expression of lipid metabolism genes were altered after oxidized LDL exposure of monocytes. Methylation of CpG sites within exon 3 of APOA5 was positively correlated with triglyceride concentration and with a lipoprotein profile associated with atherogenic dyslipidemia \[[@R53]\]. Another candidate gene study reported decreased methylation levels of the actin-related protein 2/3 complex subunit 3 (*ARPC3*) promoter-associated CpG site cg10738648 in both visceral adipose tissue and blood for carriers of the rs3759384 T allele in obese patients with hypertriglyceridemia, and showed *ARPC3* expression to be correlated with plasma triglyceride levels \[[@R55]\]. Finally, lower *TNNT1* DNA methylation levels were found to be independently associated with lower HDL-C levels and a *TNNT1* polymorphism in patients with and without familial hypercholesterolemia \[[@R29]\]. Genetic variations of the *TNNT1* locus have previously been associated with HDL-C levels in several GWAS \[[@R36]\].

MENDELIAN RANDOMIZATION: A TOOL FOR CAUSAL INFERENCE IN DNA METHYLATION STUDIES
===============================================================================

To determine whether lipids influence DNA methylation or DNA methylation causes differences in lipid levels, Mendelian randomization was put forward as a tool for causal inference in DNA methylation studies \[[@R56],[@R57]\]. Although Mendelian randomization can provide strong evidence for causal relationships, the quality of evidence provided by a Mendelian randomization study heavily relies on the underlying assumptions \[[@R58]\]. Applications and limitations of Mendelian randomization in EWAS have been recently reviewed \[[@R59]\].

Dekkers *et al.*\[[@R23]^▪▪^\] showed that differential methylation is the consequence of interindividual variation in blood lipid levels and not *vice versa*. Using multivariate Mendelian randomization, they reported an effect of blood lipids on DNA methylation at six CpG sites. A large-scale EWAS in peripheral blood reported by Mendelson *et al.*\[[@R33]^▪▪^\] identified associations between BMI and methylation at 83 replicated CpG sites, with an over-representation of lipid metabolism pathways among those CpG sites associated with gene expression changes. Eleven CpG sites revealed three-way associations, whereby DNA methylation was associated with BMI and expression, and also with BMI-associated expression changes, including the known lipid-related CpG sites within *ABCG1*, *CPT1A*, *DHCR24*, *SLC1A5*, and *SREBF1*. Using Mendelian randomization, 16 CpG sites were found to be differentially methylated as a consequence of BMI \[[@R33]^▪▪^\]. These 16 CpG sites were annotated to 12 genes, including *ABCG1.* Among the 83 BMI-related CpG sites, only cg11024682 (*SREBF1*) showed evidence for a causal effect on BMI. Genetically predicted exposure to differential methylation and *SREBF1* gene expression was associated with dyslipidemia, adiposity-related traits, and CAD \[[@R33]^▪▪^\]. Wahl *et al.*\[[@R28]^▪▪^\] subsequently showed in whole blood and adipose tissue that DNA methylation at lipid-related CpG sites is predominantly the consequence of adiposity and not the cause. Whereas Dekkers *et al.*\[[@R23]^▪▪^\] suggest that methylation of cg11024682 (*SREBF1*) is induced by triglyceride levels, the analysis of Mendelson *et al.*\'s \[[@R33]^▪▪^\] study reports a causal effect of the same CpG site on BMI, a result not confirmed by Wahl *et al.*\[[@R23]^▪▪^,[@R28]^▪▪^,[@R33]^▪▪^\]. All recently conducted Mendelian randomization studies, however, highlight the causal effect of methylation at the *ABCG1* loci on both BMI and lipid levels \[[@R23]^▪▪^,[@R28]^▪▪^,[@R33]^▪▪^\].

CONCLUSION AND FUTURE DIRECTIONS
================================

Epigenetics continues to be a promising area of research in lipid-related diseases. Current scientific knowledge does not completely explain the molecular mechanisms behind lipid metabolism and lipid-related diseases. Epigenetic modifications, such as DNA methylation, might form an additional path to understanding the mechanisms of lipid-related diseases. However, many challenges regarding the design, conduct, and interpretation of EWAS persist. The main challenges include accounting for variation in cellular heterogeneity, potential confounding effects, and resolving whether blood samples do indeed mirror relevant targeted tissues. Therefore, longitudinal cohort studies and larger sample sizes are key points for further investigations. Moreover, in addition to the development of cost-effective sequencing applications, a new array has been developed covering more than 850 000 methylation sites across the genome.

Investigation into further lipid classes, beyond the traditional blood lipids, and studies on disorders of lipid metabolism will provide new and important insights. Furthermore, other epigenetic layers need to gain importance, for example, the interplay between microRNAs and other epigenetic regulators such as histone modifications and DNA methylation. For example, it is becoming increasingly evident that post-transcriptional repression by microRNAs, a class of small noncoding RNAs, is a key layer of regulation in several biological processes, including lipid phenotypes \[[@R60]\]. The NIH Roadmap Epigenomics Consortium has generated a large collection of human epigenomes for primary cells and tissues, describing the integrative analysis of 111 reference human epigenomes generated as part of the program, profiled for histone modification patterns, DNA accessibility, DNA methylation, and RNA expression, providing a unique resource for such investigations \[[@R61]\].

Another important task is to assess, and functionally validate, causality of the reported associations, and, if we propose that a change in DNA methylation status is causal for a lipid phenotype, to assess when these changes occur \[[@R62]\]. For example, it has been indicated that for a growing fetus, malnutrition can have harmful effects on prenatal programming and contribute to the development of diseases later in life \[[@R63],[@R64]\]. Perhaps, the greatest challenge is to understand the functional consequences of the confirmed loci. Biological insights can then be translated to clinical benefits, including reliable biomarkers and effective strategies for disease prevention. Functional follow-up studies of confirmed loci will help unravel the precise molecular mechanisms at specific CpG sites, including the identification of methylation-specific binding proteins and characterization of their mode of action.

Although knowledge of epigenetic changes, such as DNA methylation, has the potential to shed light on the differences in lipid concentrations and the underlying pathways' mechanisms, the ultimate goal remains the translation of this knowledge into the effective prediction and treatment of lipid-related diseases.

Acknowledgements
================

We would like to thank Rory Wilson and Sacha E. Horn for revision of the English text.

Financial support and sponsorship
---------------------------------

*This work was supported by funding from the European Union Seventh Framework Programme under grant agreement (No. 313010) (large-scale prospective cohort studies -- BBMRI-LPC;*[*www.bbmri-lpc.org*](http://www.bbmri-lpc.org/))*, (No. 602736) (multidimensional omics approach to stratification of patients with low back pain -- PAIN-OMICS;*[*http://www.painomics.eu/*](http://www.painomics.eu/))*, and under grant agreement (No. 603288) (Systems Biology to Identify Molecular Targets for Vascular Disease Treatment -- SysVasc;*[*http://www.sysvasc.eu/*](http://www.sysvasc.eu/)*).*

Conflicts of interest
---------------------

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING
==================================

Papers of particular interest, published within the annual period of review, have been highlighted as:▪ of special interest▪▪ of outstanding interest

###### 

Epigenome-wide association studies (EWAS) of DNA methylation and lipid traits

  Annotated genes                                  CpG sites                                              Chr   TG   HDL-C   LDL-C   TC   Reference                                                                                                                                                                      Previously associated with
  ------------------------------------------------ ------------------------------------------------------ ----- ---- ------- ------- ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------
  ***CPT1A***[^a^](#TF1-1){ref-type="table-fn"}    cg00574958cg17058475cg09737197cg01082498               11    ●                         Dekkers *et al.* \[[@R23]^▪▪^\]Braun *et al.* \[[@R25]\]Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]Hedman *et al.* \[[@R24]\]                                                      **TG, LDL-C** (Pfeiffer *et al.* \[[@R15]\]Irvin *et al.* \[[@R12]\])
  *IGFBP5*                                         cg00011856                                             2     ●                         Tremblay *et al.* \[[@R26]\]                                                                                                                                                   
  *ATF1*                                           cg05655647                                             12    ●                         Tremblay *et al.* \[[@R26]\]                                                                                                                                                   
  ***SARS***[^a^](#TF1-1){ref-type="table-fn"}     **cg03725309**                                         1     ●                         Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  ***PHGDH***                                      cg16246545                                             1     ●                         Hedman *et al.* \[[@R24]\]Truong *et al.* \[[@R30]\]                                                                                                                           **BMI** (Aslibekyan *et al.* \[[@R19]\])
  ***TXNIP***                                      cg19693031                                             1     ●                         Hedman *et al.* \[[@R24]\]Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]Dayeh *et al.* \[[@R31]\]                                                                                     **TG** (Pfeiffer *et al.* \[[@R15]\])
  ***SLC7A11***                                    cg06690548                                             4     ●                         Hedman *et al.* \[[@R24]\]Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]                                                                                                              
  *GARS*                                           cg03068497                                             7     ●                         Hedman *et al.*\[[@R24]\]                                                                                                                                                      
  ***VPS25***                                      cg08857797                                             17    ●                         Hedman *et al.*\[[@R24]\]                                                                                                                                                      **BMI** (Demerath *et al.* \[[@R16]\])
  *SLC1A5*[^a^](#TF1-1){ref-type="table-fn"}       cg2711608                                              19    ●                         Hedman *et al.*\[[@R24]\]                                                                                                                                                      
  ***MYLIP***[^a^](#TF1-1){ref-type="table-fn"}    cg03717755                                             6     ●                         Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]                                                                                                                                        **T2D** (Kulkarni *et al.* \[[@R22]\])
  ***SREBF1***[^a^](#TF1-1){ref-type="table-fn"}   cg11024682cg08129017                                   17    ●    ●                    Dekkers *et al.*\[[@R23]^▪▪^\]Braun *et al.* \[[@R25]\]Hedman *et al.* \[[@R24]\]Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]                                                       **TG** (Pfeiffer *et al.* \[[@R15]\])
  ***ABCG1***[^a^](#TF1-1){ref-type="table-fn"}    cg06500161cg27243685 cg01881899cg02370100 cg01176028   21    ●    ●                    Hedman *et al.* \[[@R24]\]Braun *et al.* \[[@R25]\]Dekkers *et al.* \[[@R23]^▪▪^\]Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]Truong *et al.* \[[@R30]\]Dayeh *et al.* \[[@R31]\]   **TG, HDL-C** (Pfeiffer *et al.* \[[@R15]\])**BMI** (Arner *et al.* \[[@R18]\])
  ***SOCS3***[^a^](#TF1-1){ref-type="table-fn"}    cg18181703                                             17    ●    ●                    Ali *et al.* \[[@R27]\]                                                                                                                                                        
  ***DHCR24***[^a^](#TF1-1){ref-type="table-fn"}   cg17901584cg27168858                                   1          ●       ●       ●    Braun *et al.* \[[@R25]\]Dekkers *et al.* \[[@R23]^▪▪^\]Hedman *et al.* \[[@R24]\]                                                                                             
  *SREBF2*[^a^](#TF1-1){ref-type="table-fn"}       cg09978077cg16000331                                   22                         ●    Hedman *et al.* \[[@R24]\]Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]                                                                                                              
  *OXER1*                                          cg23759710                                             2                          ●    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  *SQLE*                                           cg00285394                                             8                  ●       ●    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  *NLRC5*                                          cg07839457                                             16                         ●    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  *GATAD2B*                                        cg07567724                                             1          ●                    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  ***PIKFYVE***                                    cg19351166                                             2          ●                    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  ***NFKBIE***                                     cg06560379                                             6          ●                    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  ***UFM1***                                       cg19750657                                             13         ●                    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  ***KLF13***                                      cg07814318                                             15         ●                    Hedman *et al.* \[[@R24]\]                                                                                                                                                     **BMI** (Demerath *et al.* \[[@R16]\])
  ***MYO5C***                                      cg06192883                                             15         ●                    Hedman *et al.* \[[@R24]\]                                                                                                                                                     **BMI, WC** (Demerath *et al.* \[[@R16]\])
  ***SPRY4***                                      cg06397161                                             5          ●                    Hedman *et al.* \[[@R24]\]                                                                                                                                                     
  ***PHOSPHO1***                                   cg02650017                                             17         ●                    Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]Dayeh *et al.* \[[@R31]\]                                                                                                               
  *SYNGAP1*                                        cg09572125                                             6          ●                    Sayols-Baixeras *et al.* \[[@R38]^▪▪^\]                                                                                                                                        

CpGs and annotated genes in bold are also described in the literature as associated with lipid phenotypes and/or lipid-related diseases (Table [2](#T2){ref-type="table"}). All associations were investigated in blood.

Chr, chromosome; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; T2D, type 2 diabetes; TC, total cholesterol; TG, triglyceride; WC, waist circumference.

^a^Expression data are available.

###### 

Epigenome-wide association studies of DNA methylation and lipid phenotypes or lipid related diseases

  Annotated genes                                    CpG sites                                      Chr   BMI   BMI%   MetS   HTGW   TG-PPL   T2D   Reference                                                                                                                                                             Previously associated with
  -------------------------------------------------- ---------------------------------------------- ----- ----- ------ ------ ------ -------- ----- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***CPT1A***[^a^](#TF2-1){ref-type="table-fn"}      **cg00574958cg17058475**                       11    ●            ●      ●      ●              Mendelson *et al.* \[[@R33]^▪▪^\]Al Muftah *et al.* \[[@R32]\]Das *et al.* \[[@R42]\]Mamtani *et al.* \[[@R41]\]Lai *et al.* \[[@R40]\]Wahl *et al.* \[[@R28]^▪▪^\]   **TG, LDL-C** (Pfeiffer *et al.* \[[@R15]\]Irvin *et al.* \[[@R12]\])**BMI** (Demerath *et al.* \[[@R16]\]Aslibekyan *et al.* \[[@R19]\])**T2D** (Kulkarni *et al.* \[[@R22]\])
  ***ABCG1***[^a^](#TF2-1){ref-type="table-fn"}      **cg06500161cg27243685cg01881899cg10192877**   21    ●                   ●      ●              Mendelson *et al.* \[[@R33]^▪▪^\]Wilson *et al.* 2017Mamatani *et al.* \[[@R41]\]Lai *et al.* \[[@R40]\]Wahl *et al.* \[[@R28]^▪▪^\]Dayeh *et al.* \[[@R31]\]         **TG, HDL-C** (Pfeiffer *et al.* \[[@R15]\])**BMI, WC** (Demerath *et al.* \[[@R16]\])**T2D** (Chambers *et al.* \[[@R20]\]Kulkarni *et al.* \[[@R22]\])
  ***DHCR24***[^a^](#TF2-1){ref-type="table-fn"}     **cg17901584**                                 1     ●                                         Mendelson *et al.* \[[@R33]^▪▪^\]Wahl *et al.* \[[@R28]^▪▪^\]Wilson *et al.* \[[@R34]\]                                                                               **WC** (Demerath *et al.* \[[@R16]\])
  ***SARS***                                         **cg03725309**                                 1     ●                                         Mendelson *et al.* \[[@R33]^▪▪^\]                                                                                                                                     
  ***SLC1A5***                                       **cg02711608**                                 19    ●                                         Mendelson *et al.* \[[@R33]^▪▪^\]                                                                                                                                     
  ***SREBF1***[^a^](#TF2-1){ref-type="table-fn"}     **cg11024682**                                 17    ●                          ●              Mendelson *et al.* \[[@R33]^▪▪^\]Al Muftah *et al.* \[[@R32]\]Lai *et al.* \[[@R40]\]Wahl *et al.* \[[@R28]^▪▪^\]Dayeh *et al.* \[[@R31]\]                            **TG** (Pfeiffer *et al.* \[[@R15]\])**BMI, WC** (Demerath *et al.* \[[@R16]\])**T2D** (Chambers *et al.* \[[@R20]\]Kulkarni *et al.* \[[@R22]\])
  ***SOCS3***[^a^](#TF2-1){ref-type="table-fn"}      **cg18181703**                                 17    ●     ●      ●                      ●     Ali *et al.* \[[@R27]\]Al Muftah *et al.* \[[@R32]\]Wahl *et al.* \[[@R28]^▪▪^\]Dayeh *et al.* \[[@R31]\]Wilson *et al.* \[[@R34]\]                                   **T2D** (Chambers *et al.* \[[@R20]\])
  ***TXNIP***[^a^](#TF2-1){ref-type="table-fn"}      **cg19693031**                                 1                                         ●     Florath *et al.* \[[@R37]\]Al Muftah *et al.* \[[@R32]\]                                                                                                              **TG** (Pfeiffer *et al.* \[[@R15]\])**T2D** (Chambers *et al.* \[[@R20]\]Kulkarni *et al.* \[[@R22]\])
  ***MYO5C***                                        **cg06192883**                                 15    ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          **BMI, WC** (Demerath *et al.* \[[@R16]\])
  *SBNO2*                                            cg07573872                                     19    ●                                         Al Muftah *et al.* \[[@R32]\]Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                             **BMI** (Demerath *et al.* \[[@R16]\])
  *PRR5L*                                            cg07136133cg00220721                           11    ●                                         Al Muftah *et al.* \[[@R32]\]Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                             **BMI** (Demerath *et al.* \[[@R16]\])
  ***APOA5***                                        **cg12556569**                                 11                               ●              Lai *et al.* \[[@R40]\]                                                                                                                                               **TG** (Pfeiffer *et al.* \[[@R15]\])
  *LPP*                                              cg16464007                                     3     ●                          ●              Wahl *et al.* \[[@R28]^▪▪^\]Lai *et al.* \[[@R40]\]                                                                                                                   
  *LY6G6E*                                           cg13123009                                     6     ●                                         Al Muftah *et al.* \[[@R32]\]                                                                                                                                         **BMI, WC** (Demerath *et al.* \[[@R16]\])
  *SMARCA4*                                          cg22898082cg17218495                           19    ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***KLF13***                                        **cg07814318**                                 15    ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          **BMI** (Demerath *et al.* \[[@R16]\])
  ***UFM1***                                         **cg19750657**                                 13    ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***VPS25***                                        **cg08857797**                                 17    ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          **BMI** (Demerath *et al.* \[[@R16]\])
  ***HOXA3***                                        cg01964852                                     7     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***SYNGAP1***[^a^](#TF2-1){ref-type="table-fn"}    cg22740603                                     6     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***PHOSPHO1***[^a^](#TF2-1){ref-type="table-fn"}   **cg02650017**                                 17    ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***SPRY4***                                        **cg13305415**                                 5     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***NFKBIE***                                       **cg06560379**                                 6     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***PIKFYVE***                                      **cg19351166**                                 2     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***SLC7A11***[^a^](#TF2-1){ref-type="table-fn"}    cg07661704                                     4     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***PHGDH***                                        cg14476101                                     1     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***IGFBP5***                                       cg05485437                                     2     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          
  ***MYLIP***[^a^](#TF2-1){ref-type="table-fn"}      **cg03717755**                                 6     ●                                         Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                                          **T2D** (Kulkarni *et al.* \[[@R22]\])
  *CACNA2D3*[^a^](#TF2-1){ref-type="table-fn"}       cg01368219                                     3     ●                                         Mendelson *et al.* \[[@R33]^▪▪^\]                                                                                                                                     
  *RPS6KA2*                                          cg17501210                                     6     ●                                         Wilson *et al.* \[[@R34]\]Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                
  *FSD2*                                             cg07728579                                     15    ●                                         Wilson *et al.* \[[@R34]\]Wahl *et al.* \[[@R28]^▪▪^\]                                                                                                                
  *STK39*                                            cg11775828                                     2     ●                                         Wilson *et al.* \[[@R34]\]                                                                                                                                            
  *CRHR2*                                            cg13134297                                     7     ●                                         Wilson *et al.* \[[@R34]\]                                                                                                                                            
  *ZNF771*                                           cg04502490                                     16          ●                                   Ali *et al.* \[[@R27]\]                                                                                                                                               
  *LIMD2*                                            cg02988947                                     17          ●                                   Ali *et al.* \[[@R27]\]                                                                                                                                               

CpGs and annotated genes in bold are also described in the literature as associated with blood lipids (Table [1](#T1){ref-type="table"}).

Chr, chromosome; HDL-C, high-density lipoprotein cholesterol; HTGW, hypertriglyceridemic waist; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; T2D, type 2 diabetes; TC, total cholesterol; TG-PPL, triglyceride postprandial responses; TG, triglyceride; WC, waist circumference.

^a^Expression data are available.
